Discovery of G Protein-Biased EP2 Receptor Agonists
†Medicinal Chemistry Research Laboratories, ‡Department of Biology & Pharmacology, and §Discovery Research Alliance, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
∥ Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8571, Japan
ACS Med. Chem. Lett., 2016, 7 (3), pp 306–311
DOI: 10.1021/acsmedchemlett.5b00455
Publication Date (Web): January 4, 2016
Copyright © 2016 American Chemical Society
Abstract
To identify G protein-biased and highly subtype-selective EP2 receptor agonists, a series of bicyclic prostaglandin analogues were designed and synthesized. Structural hybridization of EP2/4 dual agonist 5 and prostacyclin analogue 6, followed by simplification of the ω chain enabled us to discover novel EP2 agonists with a unique prostacyclin-like scaffold. Further optimization of the ω chain was performed to improve EP2 agonist activity and subtype selectivity. Phenoxy derivative 18a showed potent agonist activity and excellent subtype selectivity. Furthermore, a series of compounds were identified as G protein-biased EP2 receptor agonists. These are the first examples of biased ligands of prostanoid receptors.
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.5b00455.
- Experimental procedures of compounds, characterization data, and conditions of the biological assays (PDF)
0 件のコメント:
コメントを投稿